RTPCR testing kits are used for testing golden test processes to detect Covid19 viruses in patients.
RT PCR TEST KITS FOR COVID ARE AVAILABLE DIRECTLY FROM MANUFACTURERS IN SOUTH KOREA. No intermediaries. Please contact For quotes only if you are a buyer.
Our test kit has been approved and endorsed by Singapore's MOH (Ministry of Health) and HSA (Health Science Authority) since last year and we have been constantly supplying to the APAC countries during this period. (Japan, India, Singapore, Malaysia, Indonesia and etc.) * CE mark was attained in December 2020. * Our Tepat 1.0 SARS-CoV-2 RT-PCR provides for high-throughput, sensitive and specific detection of SARS-CoV-2 RNA extracted from nasopharyngeal swabs*. It can detect 6 copies of viral RNA per reaction with > 95% confidence. Clinical validation shows 100% sensitivity, with no cross-reaction with non-SARS-CoV-2 species. Key Highlights 1.5 hours from RNA to results Multiplex RdRp and M viral genes detection enhances sensitivity and specificity 100% coverage with 100% identity of all SARS-CoV-2 genomes in the world Detects 6 copies of viral RNA Whole process control: human RNase P
Cat No : RP10243X. Detection of COVID-19 specific target genes in a single tube- Reliable result with three target genes- Results within 1 hour and 50 minutes after extraction- Convenient work now on the automated MDx platform- Suitable for high-throughput- Providing whole process control for assay validity- Automated data interpretation with Seegene Viewer.
Product Details: Number of Reactions(Preps) per Kit : 100 Brand : Seegene ICMR(Govt) Approved : Yes Test Method : (SARS-CoV-2) RT-PCR Test Time : 2 Hours Cat. No : RP10243X -Detection of COVID-19 specific target genes in a single tube- Reliable result with three target genes- Results within 1 hour and 50 minutes after extraction- Convenient workow on the automated MDx platform- Suitable for high-throughput- Providing whole process control for assay validity- Automated data interpretation with Seegene Viewer Additional Information: Delivery Time: Immediate
Product Description : The PaxView COVID -19 real-time RT-PCR Kit detects the novel coronavirus, COVID-19 using one-step real-time RT-PCR in a single tube intended for in vitro diagnostic use. The target genes for the detecton of the virus are Orf1ab and N gene. The sequence of primers and probes for the amplification were adapted from sources published by China CDC and WHO. The kit includes primers and probe set targeting the human RNase P gene that serves as an internal positive control for the real-time RT-PCR. Price of product ( USD price or FOB price) : 1no testing 20 USD 1kit testing = 96no testing 1kit = 96no * 24 USD = 2208 USD (base on Qty negociable) Product origin ; korea Key Specifications/Special Features : 1. with in 3hour testing result in come 2. One item 96person can check 3. 100% correct result coming then other method 4. It is same process in korea Minimum Order Size and Packgaing details : 50kit in box 500 x 460 x350 6kg MOQ : 500
ExProbeTM SARS-CoV-2 qPCR Testing Kit EU CE Marked, US FDA EUA Approved, Taiwan FDA EUA Approved Intended Use: To detect RdRP/N/E RNA SARS-CoV-2 (COVID-19) in NP/O swabs and sputum. Product Format: 96 tests/kit Kit Contents: PCR Mix, Enzyme Mix, Pos. Control, Neg. Control and Instruction For Use. Storage / Stability: -20C + 5C / 6 months, repeat freeze thaw x 4. Testing kit is compatible for ABI7500,Roche 4800, TBG Q6000 qPCR Systems Reproducibility / Precision 100% Concordant across 3 lots with CV + 5% Limits of Detection (LOD) 50 copies/reaction Performance Comparison* Positive Samples 5 / 5 Negative Samples 199/200
* KOREA Brand : 1) OSANG HealthCare 2) SD BIOSENSOR 3) Genematrix * Test Type : RT-PCR * Accuracy rate : 98% * Read result time : One and half hour ~ * Package : 96 test or 100 test / 1 Kit, 1 box * Price : FOB Korea 1,300 ~ 1,650 USD / 100 test * MOQ : 10,000 test * Payment Terms : T/T 50% advance and Balance SGS inspection * Product Certificate : KFDA, CE, FDA
RT PCR-Detection Kit
The COVID-19 RT-PCRT est is a real-time reverse transcription polymerase chain reaction (rRT -PCR) test. The test can be run in a singleplex format (three individual assays) or multiplexed into a single reaction and amplification set up.
COVID-19 RT-PCR TEST - NO RNA PURIFICATION NEEDED! Results in less than 60 minutes, very easy-to-use. Made in USA, with clinical validations all over the world. FDA-EUA approved and CE cleared.
Lowest detection line:200 copy/ml CE marks
25 tests per box
Intended Use Novel Coronavirus (2019-nCoV) Real-time RT-PCR Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the 2019-nCoV in oropharyngeal swabs and bronchoalveolar lavage fluid collected form individuals suspected of COVID-19 by their healthcare provider. About SARS-CoV-2 Specific antibodies will be produced within days to weeks as the immune system makes immune defense against the SARS-CoV-2 infection. Total antibody detection is an aid in the diagnosis of patients with suspected SARS-CoV-2 infection in conjunction with clinical symptoms and result of other diagnostic methods. The test result should not be used as the sole basis for diagnosis and exclusion of SARS-CoV-2 infection. Total antibody may not be detected in the first few days of infection. SARS-CoV-2 neutralizing antibody is a protective soluble protein secreted by adaptive immunizing cells after inoculation with SARS-CoV-2 vaccine or infection with SARS-CoV-2. These antibodies can specific bind with virus RNA binding domain (RBD) to block the binding of RBD with angiotensin-converting enzyme 2 (ACE2) on human cells surface, thus prevent the virus or its genetic material into the human cell and virus infection. Benifits of the Kit 1) Room Temperature Transportation 2) Cost-Effective Shipping The shipping is at room temperature, with no need of cold chain shipping. 3) Highly Sensitive, Highly Specific Highly sensitive and highly specific for 2019-nCoV, reliable identification of COVID-19. 4) Environmentally Friendly The kit needs neither bulky packaging nor cold chain shipping. Contents A kit contains: Package specifications: 24 tests/kit, 48 tests/kit 1) 2019-nCoV-PCR Master Mix (Lyophilized Powder): 1 bottle/box 2) 2019-nCoV-PCR Positive Control (Lyophilized Powder):1 bottle/box 3) 2019-nCoV Diluent: 1 bottle/box 4) User Manual Note: Do not mix or interchange different batches of kits.
ThermoFisher Scientific Accula System Rapid & Reliable RT-PCR Test for Corona in 30mins Product Details: Number of Reactions(Preps)/Kit : 25 Brand : Thermo Test Method : (SARS-CoV-2) RT-PCR Sample Type : Nasal Swab Test Time 30 min The Accula System from Thermo Fisher Scientific is a rapid diagnostic platform that combines the accuracy of RT-PCR with the simplicity, convenience, and procedural familiarity of traditional rapid immunoassays. The Acculaâ?¢ SARS-CoV-2 Test has received an Emergency Use Authorization (EUA) from the FDA for the detection of SARS-CoV-2 in Clinical Laboratory Improvement Amendments (CLIA) waived environments. Designed for use with the palm-sized Accula Dock, the Accula SARS-CoV-2 Test provides reliable, qualitative results in approximately 30 minutes
The COVID-19 RT-PCR Detection Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper and lower respiratory specimens (such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. 263a, to perform high complexity tests. Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper and lower respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infective status. The agent detected may not be the definite cause of disease. Positive results do not rule out bacterial co-infection with other viruses. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. The COVID-19 RT-PCR Detection Kit is intended for use by qualified trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The COVID-19 RT-PCR Detection Kit is only for use under the Food and Drug Administration's Emergency Use Authorization. PRINCIPLE OF DETECTION This product is a fluorescent probe-based Taqman RT-PCR assay system. Firstly, the RNA of SARS-CoV-2 will be reverse transcribed into cDNA by reverse transcriptase, and then PCR amplification will be performed with cDNA as template. During amplification of the template, the TaqMan probe will be degraded due to the 5'-3 polymerase activity and exonuclease activity of Taq DNA polymerase, then the separation of fluorescent reporter and quencher enables the fluorescent signal to be detected by instrument. The ORF1ab gene of SARS-CoV-2 will be detected qualitatively by FAM channel, the N gene of SARS-CoV-2 will be detected qualitatively by JOE channel, the E gene of SARS-CoV-2 will be detected qualitatively by ROX channel, and the internal reference will be detected by CY5 channel. dUTP and UNG enzyme are used in the kit to prevent contamination of the amplified products. Internal reference is used in the kit for quality control starting from sample collection
Indication: Qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens (such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) from individuals suspected of COVID-19 by their healthcare provider. Emergency use of this test is limited to authorized laboratories. Authorized Laboratories: Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform high complexity tests. This letter is in response to your1 request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for emergency use of your product,2 pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3). On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act. Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization. I. Criteria for Issuance of Authorization I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that: 1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus; 2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and, 3. There is no adequate, approved, and available alternative to the emergency use of your product. 4 II. Scope of Authorization I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.
Commodity: Covid-19 RT-PCR Detection Kit Spec.96 tests/kit Price:FOB SHANGHAI USD3.30/test, USD316.8/kit $3.60/TEST CIF NY AIRPORT OR OTHER MAJOR AIRPORTS USA OR EUROPE OR S. AMERICA OR MIDDLE EAST Payment: T/T ADVANCE 50% BALANCE BEFORE DEPARTURE OR Sight Irrevocable TRANSFERABLE LC Delivery: By AIR, 50days after receipt and confirmation of LC
Sample Types : Including Nasopharyngeal swab, Oropharyngeal swab, Sputum Controls : Internal control, UNG enzyme and dUTP used to reduce risk of contamination, false positive and false negative results Product Information Upper and lower respiratory specimens such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate. Authorized Laboratories Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform high complexity tests. About Emergency Use Authorization (EUA) This test (1) has not been FDA cleared or approved, (2) has been authorized by FDA under an EUA for use by authorized laboratories, (3) has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and (4) is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C.360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The KAiRA 2019-nCoV PCR Detection Kit is a one step RT-PCR reagent system, based on real-time PCR technology, for the qualitative detection and differentiation of lineage B-beta Coronavirus and severe acute respiratory syndrome coronavirus 2 specific RNA. The test kit has FDA and CE Approval and comes in packs of 100 tests. In combination with Dr PCR the test results for PCR Testing can be given in under an hour and are compatible for use for international travel requirements. Unit - Kit (1 kit contains 100 tests) Unit Price - $900 per kit